About the journal
Kidney Cancer is an open-access journal published by SAGE Publishing in United Kingdom, publishing in english. It is listed in DOAJ and PUBMED according to the sources read. Declared publication charge: 2,800 USD. Declared review time at DOAJ: 16 weeks. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- SAGE Publishing
- ISSN
- 2468-4562 · 2468-4570
- Country
- United Kingdom
- Languages
- english
- Access
- Open access
- Declared publication charge
- 2,800 USD
- Articles in DOAJ
- 204
- Declared review time
- 16 weeks
- Declared peer-review model
- peer_review
- Official website
- https://journals.sagepub.com/home/KCA
Index listings
- DOAJ · 2023-06-12
- PUBMED · 2017-07-26
- Indexing
- DOAJ · PUBMED
- APC
- 2,800 USD
- Declared review time (DOAJ)
- 16 weeks — journal-declared only (not measured)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Articles in DOAJ
204
Most recent article
6 months ago
Average review time (journal-declared via DOAJ)
16weeks
Works in OpenAlex
259
Last recorded publication year
2025
h-index
15
i10-index
34
From OpenAlex open data (CC0).
Editorial & policy12
- Last DOAJ review date
- 2025-06-11
- Added to DOAJ
- 2023-06-12
- Declared plagiarism screening
- Declared
- Other fees beyond APC
- No
- Declared digital preservation
- CLOCKSS
- Observed digital preservation (Keepers registry)— snapshot 2026-10-05
- CLOCKSSPortico
- Editorial board
- Official page ↗
- Open references deposited at Crossref
- 91%
- ORCID iDs in current deposits
- 56%
- Enrolled in Crossref Similarity Check
- ✓
- Deposits licence metadata at Crossref
- ✓
- APC waiver policy
- View policy
- Peer-review policy
- View policy
Identity & continuity2
- Source type
- journal
- NLM unique ID (PubMed)
- 101735372
Classification4
Subjects (DOAJ)
LCC codes
Subject areas
- Renal cell carcinoma treatment
- Renal cell carcinoma treatment
- Renal and related cancers
- Renal and related cancers
- Cancer Genomics and Diagnostics
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Cancer Immunotherapy and Biomarkers
Show all subjects (50)
- Bladder and Urothelial Cancer Treatments
- Bladder and Urothelial Cancer Treatments
- Economic and Financial Impacts of Cancer
- Economic and Financial Impacts of Cancer
- Pancreatic and Hepatic Oncology Research
- Pancreatic and Hepatic Oncology Research
- Health Systems, Economic Evaluations, Quality of Life
- Health Systems, Economic Evaluations, Quality of Life
- Ferroptosis and cancer prognosis
- Ferroptosis and cancer prognosis
- Epigenetics and DNA Methylation
- Epigenetics and DNA Methylation
- Multiple and Secondary Primary Cancers
- Multiple and Secondary Primary Cancers
- Cancer, Hypoxia, and Metabolism
- MRI in cancer diagnosis
- MRI in cancer diagnosis
- Cancer, Hypoxia, and Metabolism
- Cancer Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- Management of metastatic bone disease
- Management of metastatic bone disease
- Tuberous Sclerosis Complex Research
- Genetic and Kidney Cyst Diseases
- Genetic and Kidney Cyst Diseases
- Tuberous Sclerosis Complex Research
- Medical Imaging and Pathology Studies
- Chemotherapy-induced organ toxicity mitigation
- Renal and Vascular Pathologies
- Brain Metastases and Treatment
- Chemotherapy-induced organ toxicity mitigation
- Brain Metastases and Treatment
- Medical Imaging and Pathology Studies
- Renal and Vascular Pathologies
- Cardiac tumors and thrombi
- Advanced Radiotherapy Techniques
- Advanced Radiotherapy Techniques
- PI3K/AKT/mTOR signaling in cancer
- Cardiac tumors and thrombi
- Renal Diseases and Glomerulopathies
- PI3K/AKT/mTOR signaling in cancer
- Renal Diseases and Glomerulopathies
Keywords (DOAJ)
- kidney cancer
- renal cell carcinoma
- renal cancer
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
The journal's record in other sources:Web of Science MJLDOAJ